Objectives: Masitinib, a novel, multitargeted, tyrosine kinase inhibitor, is compared with imatinib (Gleevec) in this phase III trial. Investigators ask whether it can improve progression-free survival; overall survival is a secondary outcome measure.
Key entry or exclusion criteria: Patients must have metastatic or locally advanced nonresectable or recurrent postsurgery GIST.
Locations: 43 sites.
Goal: 222 patients.
Study sponsor: AB Science.
Links for more information: clinicaltrials.gov/ct2/show/study/NCT00812240
NIH clinical trials identifier: NCT00812240